Tag
Nabla Bio's new paper (JAM-2) expands generative drug design to multispecifics and the intracellular proteome, achieving zero-shot design of a KRAS G12V-targeting bispecific that recruits T cells for picomolar cell killing.
Nabla Bio unveils JAM-2, a model for zero-shot drug design achieving atomic-precision, computationally designed multispecific antibodies and dual-variant KRAS multispecifics with high potency and selectivity, validated with Cryo-EM and wet-lab experiments.